Placebo-controlled clinical trials of recombinant human interleukin-11 (rhIL-11, also known as oprelvekin [Neumega]) in patients with nonmyeloid malignancies have demonstrated significant efficacy in preventing postchemotherapy
Craig H. Reynolds, MD
Advertisement
Articles by Craig H. Reynolds, MD
Advertisement
Latest Updated Articles
- Clinical Efficacy of rhIL-11
Published: September 1st 2000 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
What Path to Approval Has Dasatinib Taken in CML/ALL?
2
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
3
Response Rates Show Promise in Phase 1 trial Involving ASCT in Metastatic PDAC
4
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
5
